Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Jan 06, 2021 2:12pm
151 Views
Post# 32234502

RE:RE:Antibe stuck in limbo

RE:RE:Antibe stuck in limboI agree with MUGS. At the same time, its a game of chicken between shareholders and ATE; whose going to blink first. ATE needs the SP to uplist confidently and retail shareholders are looking for a quick(ish) exit strategy; which hinges on upcoming NRs.  No telling how the NR will be worded. They botched a few NRs before, and the worst one was the latest p2b results. 

I'm certainly in ATEs corner, but this stagnation in SP might also be due to a situation of bit-once-twice-shy, when comes to ATE strategic moves. That is part of the risk I suppose, with this company. Overall, I'm very much bullish, and patience will pay off. Best to avoid the day to day SP and realize that fundementals are excellent. This will attract the right fit for partnership(s). Which makes skeptical of further dilution. 

Also, keep a level head, as the bashers and shorters are out. Not to mention, old dusty boy, who has become my favorite basher so far. While hes still on my ignore list, the responses he gets of out people here is very entertaining haha!
<< Previous
Bullboard Posts
Next >>